Synthesis of cetyl myristoleate and evaluation of its therapeutic efficacy in a murine model of collagen-induced arthritis

Kenneth W. Hunter, Jr.,*, Ruth A. Gault, Jeffrey S. Stehouwer, Suk-Wah Tam-Chang

Department of Microbiology, University of Nevada School of Medicine, Reno, NV 89557, USA
Department of Chemistry, University of Nevada, Reno, NV 89557, USA

Accepted 3 September 2002

Abstract

Cetyl myristoleate (CM) was reported by Diehl and May [J Pharm Sci 83 (1994) 296] to block inflammation and prevent adjuvant-induced arthritis in rats. To verify this earlier work, we have synthesized pure CM and tested its anti-arthritic properties in a collagen-induced arthritis model in DBA/1LacJ mice. Multiple intraperitoneal injections of CM in 450 and 900 mg kg\(^{-1}\) doses resulted in a significantly lower incidence of disease and caused a modest but significant diminution in clinical signs in those mice that developed arthritis. CM administered in daily oral doses of 20 mg kg\(^{-1}\) also reduced the incidence of arthritis and caused a small reduction in the clinical signs in mice that developed arthritis. Although the protective effect of CM in collagen-induced arthritis observed in the present study was less dramatic than that reported earlier, our results confirm the anti-arthritic properties of pure CM.

Keywords: Cetyl myristoleate; Synthesis; Collagen-induced arthritis; Inflammation

1. Introduction

Cetyl myristoleate (CM) is the ester of cis-9-tetradecenoic acid (myristoleic acid) and 1-hexadecanol (cetyl alcohol). CM was originally isolated as a natural product from a NIH Swiss albino mouse strain that was resistant to adjuvant-induced arthritis [1]. When tested in a rat adjuvant arthritis model, this compound was shown to have striking anti-arthritic properties, albeit when used in very high doses. These workers later synthesized CM and demonstrated a similar protective effect. Nutraceuticals containing CM are widely used for indications of pain and inflammation relief, and with the exception of a short report suggesting a positive clinical effect of cerasomol-CM in patients with fibromyalgia [2], no follow-on studies have been published to confirm any biological properties of this fatty acid ester. Moreover, because over-the-counter preparations of CM contain free fatty acids that have been shown to modulate inflammation in arthritis and other inflammatory diseases [3], it was important to confirm that pure CM has anti-arthritic properties. Therefore, in this study we have synthesized pure CM and tested its anti-arthritic properties in a mouse collagen-induced arthritis model. We report here that pure CM in doses of 450 and 900 mg kg\(^{-1}\) given intraperitoneally (i.p.) caused a significant reduction in both the incidence and severity of arthritis in mice. In addition, CM given orally in doses of 20 mg kg\(^{-1}\) significantly reduced the incidence and caused a modest reduction in the severity of arthritis.

2. Materials and methods

2.1. Animals

Six- to eight-week-old female DBA/1LacJ mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA). The animal protocol was approved by the University of Nevada, Reno Institutional Animal Care and Use Committee.

2.2. Collagen-induced arthritis model

In the first study, each of 30 female DBA/1LacJ mice was injected intradermally at two sites on their shaved backs with a total of 100 mg of bovine type II collagen (Chondrex, Redmond, WA, USA) emulsified in complete Freund’s adjuvant (CFA, Difco, Detroit, MI, USA).
mice were randomized into three groups of 10 mice, and on day 12 each group was injected via the i.p. route with 100 μl of either phosphate buffered saline (PBS, vehicle control), 450 mg kg⁻¹ CM, or 900 mg kg⁻¹ CM. The PBS or CM injections were repeated every third day until day 30 post arthritis induction (seven total doses). Note that the dosages of CM were chosen based on those used in the original study by Diehl and May [1]. It should also be noted that CM is very insoluble in PBS, so the correct dose was added as a layer on 100 μl of PBS, pulled into a 1 cm³ tuberculin syringe, and injected as a “suspension” of CM in PBS. The mice were observed daily for clinical signs of arthritis.

In the second study, 20 mg kg⁻¹ of CM was given per os (p.o.) to the mice on a daily basis throughout the course of the experiment. The CM was adsorbed onto a 1 mg food pellet (P.J. Noyes Company, Lancaster, NH, USA), and each animal was fed one CM-treated or control pellet each day prior to ad libitum feeding of normal mouse chow. Mice were fasted from 19:00 to 07:00 h to facilitate consumption of the food pellet. The study consisted of 31 female DBA/1LacJ mice, 28 of which were injected with bovine type II collagen as described above. In a variation from the procedure in the first study, the mice were given a booster immunization with type II collagen in Freund’s incomplete adjuvant on day 28. Fourteen mice were given the daily p.o. CM treatment, while 14 were given placebo (a food pellet without CM). Three mice were given the CM treatment, but were not immunized 14 were given placebo (a food pellet without CM). Three mice were given the CM treatment, but were not immunized with type II collagen. Mice were observed daily for signs of arthritis just as described earlier, and each mouse was weighed daily.

2.3. Statistical analysis

The percentage of mice showing any signs of arthritis was determined for control and CM treatment groups, and a binomial test used to determine the significance of the difference in incidence of disease [4]. The severity of arthritis was evaluated on a 5-point clinical scale (Table 1), and the significance of differences between the means of these maximum severity scores for control and CM-treated groups was compared by Student’s t-test.

2.4. Histopathology

Mice were sacrificed with halothane, and then a portion of their hind limb extending 2 mm proximal and distal to the ankle joint was excised and placed in 10% neutral buffered formalin. After fixation, the bone was decalcified using Decal-Stat (American Master®Tech, Lodi, CA, USA), and then the tissues were processed in an automated tissue processor with final embedding in paraffin. Sections were cut with a microtome at 7.5 μm, mounted on slides, and then stained with standard haematoxylin and eosin (H&E). Thin sections were examined with a Nikon Photomicroscope under bright field illumination, and photographs of sections were made with a Kodak digital camera.

2.5. Synthesis and analysis of cetyl myristoleate

Since pure CM is not commercially available, it was synthesized by the method described below: Myristoleic acid (cis-9-tetradecenoic acid) and cetyl alcohol (1-hexadecanol) were purchased from Aldrich, Milwaukee, WI, USA. Flash silica gel #02826-5, 32–63 μm particle size, 60 Å pore size was obtained from Scientific Adsorbents, Inc., Atlanta, GA, USA, and TLC Plates #5719-2 silica gel 60 (DE1); 250 μm thickness were obtained from EM Sciences, Agawam, MA, USA. Visualization was done with cerium sulfate/ammonium molybdate in H₂SO₄ (10% v/v).

H and ¹³C Nuclear Magnetic Resonance (NMR) spectra were obtained on a Varian Unity Plus NMR spectrometer at 500 and 125 MHz, respectively, and are referenced to internal TMS. Infrared (IR) spectra were obtained on a Perkin-Elmer Spectrum 2000 FT-IR spectrometer. High Resolution Mass Spectrometry (HRMS) was performed by the University of California, Riverside Mass Spectrometry facility.

Myristoleic acid (1.11 g, 4.91 mmol), cetyl alcohol (2.57 g, 10.62 mmol, 2.2 equivalents), p-toluene sulfonic acid monohydrate (0.52 g, 2.75 mmol, 0.6 equivalent), and benzoene (200 ml) were heated at reflux under N₂(g) for 22 h with azeotropic removal of water. The solvent was removed to give an off-white solid that was vacuum flash chromatographed on silica (9 cm x 4 cm w. CHCl₃), TLC Rₖ = 0.58 to afford 2.01 g (91%) of a clear oil. HRMS (DEI) m/z; calculated for C₂₁H₃₆O₂ (M⁺): 450.4437; found: 450.4454; IR (neat/NaCl) 3294, 1745, 1655, 721 cm⁻¹.¹H NMR (500 MHz, CDCl₃) 5.36–5.33 (m, 2H, J = 3 Hz), 4.05 (t, 2H, J = 6.8 Hz), 2.29 (t, 2H, J = 7.8 Hz), 2.01 (m, 4H, J = 3 Hz), 1.61 (m, 4H, J = 6.8 Hz), 1.30–1.26 (br, d, J = 38 Hz). 0.89 (p, 6H, J = 7.5 Hz). ¹³C NMR (125 MHz, CDCl₃) 174.16, 130.13, 129.97, 64.61, 34.62, 32.18, 32.15, 29.92, 29.91, 29.90, 29.88, 29.87, 29.80, 29.75, 29.58, 29.48, 29.38, 29.35, 29.32, 28.88, 27.27, 27.13, 26.16, 25.23, 22.91, 22.56, 14.32, 14.20.

Table 1

Clinical scale for assessing development of arthritis in mice

<table>
<thead>
<tr>
<th>Score</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>No evidence of erythema or edema</td>
</tr>
<tr>
<td>2</td>
<td>Erythema and mild edema confined to midfoot (tarsals) or ankle joint, or front paw and wrist (carpals)</td>
</tr>
<tr>
<td>3</td>
<td>Erythema and edema extending from the ankle joint to the tarsals, or from the elbow joint to the carpals</td>
</tr>
<tr>
<td>4</td>
<td>Erythema and moderate edema from the ankle to the metatarsal joints, or from the elbow to the metacarpal joints</td>
</tr>
<tr>
<td>5</td>
<td>Significant erythema and edema of all major joints of at least one limb</td>
</tr>
</tbody>
</table>
CM was successfully synthesized from cis-9-tetradecenoic acid and 1-hexadecanol using a modification of the original method described by Diehl and May [1]. The end product was a clear oil liquid at room temperature. Using NMR, IR, and HRMS analysis methods, the synthetic procedure described yielded a product consistent with the known structure of cetyl myristoleate (C_{30}H_{58}O_{2}; MW, 450.7803; see Fig. 1).

In the first experiment male DBA/1LacJ mice were given i.p. injections of CM beginning on day 12 following induction of arthritis and continuing every third day until day 53. As can be seen in Table 2, 7 of 10 control animals (70%) showed signs of arthritis, whereas only 3 of 10 (30%) and 4 of 10 (40%) mice developed signs of arthritis in the 450 and 900 mg kg\(^{-1}\) CM-treated groups, respectively. Table 3 shows that clinical signs of arthritis tended to develop more rapidly in the PBS control than in the CM-treated groups, and the severity scores were significantly different by day 57. Moreover, the maximum severity scores of both CM-treated groups were significantly different from the PBS controls.

In the second experiment, mice were given daily oral doses of a saline-treated food pellet or 20 mg kg\(^{-1}\) CM in the placebo group, 65% of the mice showed some signs of arthritis (independent of severity), whereas only 36% of the CM-treated mice showed any signs of arthritis. Beginning on day 32, and more prominently on days 36 and 42, the placebo-treated control mice had higher average severity scores than the mice given daily oral doses of CM. Although the differences between the means of these severity scores did not achieve significance at the usual 95% confidence level, the day 42 results were significant at the 90% confidence level (one-tailed \(t\)-test). In addition, when the maximum severity score for each mouse was determined, there was a difference between the CM-treated mice and placebo controls significant at \(P = 0.13\). It should also be pointed out that two of the placebo mice showed signs of systemic inflammatory disease and died on days 43 and 44, respectively. No CM-treated mice showed any signs of systemic inflammatory disease. The food deprivation regimen did not cause a significant decrease in the weights of the mice when compared to ad libitum fed controls (data not shown).

Gross examination of affected limbs revealed significant erythema and edema characteristic of inflammatory joint disease. Fig. 2 compares the normal histology of the mouse ankle joint with the histopathology seen in an animal with collagen-induced inflammatory joint disease (severity score 5). It should be noted that the normal joint space is lined with a thin layer of synovium overlaying the cartilaginous layer. Deep to the cartilage is hard bone, which in these decalcified sections, appears as an eosinophilic matrix. The synovium is relatively acellular and can be seen at the corner of the joint space. In contrast to the normal histology of the mouse joint, the arthritic mouse joint shows characteristic signs of inflammation. In this example, the normal architecture of the cartilaginous layer has been disrupted with a

<table>
<thead>
<tr>
<th>Table 2: Effect of CM on the incidence of collagen-induced arthritis in DBA/1LacJ mice</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Group</strong></td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>First study</strong></td>
</tr>
<tr>
<td>PBS i.p. control</td>
</tr>
<tr>
<td>450 mg kg(^{-1}) i.p. CM</td>
</tr>
<tr>
<td>900 mg kg(^{-1}) i.p. CM</td>
</tr>
<tr>
<td><strong>Second study</strong></td>
</tr>
<tr>
<td>Placebo control</td>
</tr>
<tr>
<td>20 mg kg(^{-1}) CM orally</td>
</tr>
</tbody>
</table>

\(1\) Number of mice that develop any clinical signs of arthritis/total number of mice.

\(2\) Binomial test [13].

<table>
<thead>
<tr>
<th>Table 3: Effect of CM on clinical severity scores in DBA/1LacJ mice with collagen-induced arthritis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Day</strong></td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>First study</strong></td>
</tr>
<tr>
<td>28</td>
</tr>
<tr>
<td>36</td>
</tr>
<tr>
<td>43</td>
</tr>
<tr>
<td>57</td>
</tr>
<tr>
<td><strong>Maximum</strong></td>
</tr>
</tbody>
</table>

\(P < 0.05\) vs. PBS control (Student’s \(t\)-test).

\(4\) Binomial test [13].

\(5\) Maximum severity score observed during course of experiment.

Please note that this text is a natural representation of the document and not a formal table or figure format.
Fig. 2. Example of the histopathology of type II collagen-induced arthritis in the DBA/1LacJ mouse. H&E stain of decalcified sections of the ankle joints from mice on day 45 following immunization with collagen. (A) Mouse treated with 450 mg kg⁻¹ CM as described in Section 2; (B) control mouse given saline on same regimen. Note the profound inflammatory changes and erosion seen in the joint of the control mouse.

locus of intense inflammation, characterized by the presence of macrophages, neutrophils, and fibroblasts. The inflammation has caused a near total erosion of the cartilaginous layer of the joint, and the erosion has extended into the bone and approaches the marrow cavity. In addition, there is evidence of an intense inflammatory synovitis. The histopathology seen in the mouse collagen-induced arthritis model is consistent with that seen in both human rheumatoid arthritis and osteoarthritis.

4. Discussion

The only paper describing an effect of CM on arthritis was a short report published by Diehl and May [1]. These authors isolated CM from the arthritis-resistant NIH Swiss albino mouse, and they also reported its isolation from “wild” mice. The only other report of CM as a natural product was in an abstract that identified CM in a mixture of waxes in the anal gland of male beavers, *Castor fiber* (L.) (cited from [1], Groenneberg TO, Chem Abstr 91:190204u). Diehl and May also synthesized the molecule using a method similar to that used in the present study. They used a rat adjuvant arthritis model and demonstrated that very high doses of CM administered parenterally significantly reduced the severity of arthritis. In contrast, in our first study we found more modest though statistically significant anti-arthritic effects in the mouse collagen-induced arthritis model using similar doses of CM delivered intraperitoneally. The differences noted might be explained by the differences in models, although both animal species serve as good models of rheumatoid arthritis in humans. The susceptibility of mice to collagen-induced arthritis is strongly linked to the major histocompatibility complex (MHC), with mice of the H-2q and H-2r haplotypes being most susceptible [5,6]. The H-2q haplotype DBA/1LacJ that we employed is the most commonly used mouse strain for these studies. Immunization of genetically susceptible mice with bovine type II collagen in adjuvant induces the production of cross-reacting anti-collagen antibodies that bind to murine type II collagen in the synovia of the joints, and such binding precipitates a local inflammatory response characterized by macrophage activation, release of proinflammatory cytokines, neutrophil and macrophage-mediated destruction of the synovia, and eventually erosion of the cartilage and bone [7,8]. Adjuvant-induced arthritis, on the other hand, does not rely on the specific induction of anti-collagen antibodies by immunization, and thus is not MHC restricted [9]. Rather, adjuvant-induced arthritis manifests as a more generalized inflammation localized to the joint spaces, although the histologic picture is similar in both forms of arthritis [10,11].

As was already mentioned, the parenteral doses used in the Diehl and May study were exceptionally high. Nevertheless, we tested these same doses in our collagen-induced arthritis system to verify an anti-arthritic effect. Having demonstrated an effect, we chose to evaluate CM in a dose and route more in line with those provided in nutraceuticals and for which there is anecdotal evidence of effectiveness in humans. We found that a 20 mg kg⁻¹ dose given daily starting on the day of arthritis induction significantly reduced the incidence of disease in DBA/1LacJ mice, and caused a small though statistically non-significant diminution of clinical signs in those animals that developed arthritis. Although the mice in this second study were given a booster immunization of type II collagen in IFA on day 28, the progression of the disease was slower and of less magnitude (i.e., no maximum severity scores >4) than was seen in the first collagen-induced arthritis study in which mice were only given the initial type II collagen immunization in CFA. It is possible that the type II collagen immunogen was partially denatured during the preparation process, or that the batch of CFA used was less potent. Nevertheless, the mice did present with clinical signs of arthritis that allowed us to easily score the progression of disease and to make valid comparisons between treatment groups.

Though an anti-arthritic effect of CM was demonstrated in the present study, the mode of action of this fatty acid alcohol ester remains to be discovered. While intact CM may be responsible for the observed anti-arthritic effects, it is possible that the ester is hydrolyzed in vivo and the 14-carbon free fatty acid (myristoleic acid) is the active pharmacologic agent. Although there are no reports of an anti-arthritic
effect of myristoleic acid, an anti-inflammatory effect has been demonstrated for oleic acid, a related \( n-9 \) fatty acid \[12\]. In addition, the \( 18:2n-9 \) fatty acid linoleic acid has been shown to have anti-arthritic effects in humans in some studies \[13,14\], although this has not been confirmed in others \[15\]. There is even more convincing evidence that dietary supplementation with \( n-3 \) and \( n-6 \) polyunsaturated fatty acids from fish oils reduces inflammation and clinical signs in humans with rheumatoid arthritis \[16–18\]. There is even more convincing evidence that dietary supplementation with \( n-3 \) and \( n-6 \) poly-unsaturated fatty acids from fish oils reduces inflammation and clinical signs in humans with rheumatoid arthritis \[16–18\]. The anti-inflammatory effect of fatty acids has been attributed to stabilization of cell membranes, inhibition of the formation of inflammatory mediators, and protection against oxidation \[19,20\]. Clearly, with the demonstration that CM has an anti-arthritic effect, further studies on its mode of action, pharmacokinetics, and pharmacodynamics are warranted.

Acknowledgements

This work was supported in part by an Applied Research Initiative Matching Grant between the State of Nevada and The Henry Rushing Fund. We thank Brandon Carter for able technical assistance.

References


